Stay updated on Pembrolizumab in Advanced Penile Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced Penile Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced Penile Cancer Clinical Trial page
- Check2 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check9 days agoChange DetectedA banner announces NIH’s website transition and says content may use “Super Intelligence” in place of “Artificial Intelligence.” The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check16 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check44 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, with a minimal header and a Home link. The previous study details and sections appear to be removed.SummaryDifference18%

- Check65 days agoChange DetectedThe page revision was updated from v3.6.5 to v3.6.6, indicating a minor refresh of the entry that does not modify study data, eligibility criteria, or results.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Advanced Penile Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced Penile Cancer Clinical Trial page.